Literature DB >> 20460538

Glioma cell populations grouped by different cell type markers drive brain tumor growth.

Lars Prestegarden1, Agnete Svendsen, Jian Wang, Linda Sleire, Kai Ove Skaftnesmo, Rolf Bjerkvig, Tao Yan, Lasse Askland, Andreas Persson, Per Øystein Sakariassen, Per Øyvind Enger.   

Abstract

Although CD133 has been proposed as a marker for brain tumor-initiating cells, studies show that a tumorigenic potential exists among CD133(-) glioma cells as well. However, it is not established whether the ability of CD133(-) cells to form tumors is a property confined to a small subpopulation, rather than a common trait associated with most glioma cell types. Thus, we used lentiviral vectors expressing green fluorescent protein under lineage-specific promoters to identify CD133(-) glioma cells expressing Nestin, glial fibrillary acidic protein (GFAP), and neuron-specific enolase (NSE). Flow cytometry analysis showed the presence of CD133(-) subpopulations expressing these markers in glioma cell lines and in primary cultures from human glioblastoma (GBM) biopsies. Moreover, analysis of cell cycle distribution showed that subgroups expressing Nestin, GFAP, and NSE uniformly contained actively cycling cells, when cultured in serum-containing medium and stem cell medium. These subpopulations were fluorescence-activated cell sorted from CD133(-) U373 glioma cells and implanted intracerebrally in severe combined immunodeficient mice. Moreover, we implanted Nestin-, GFAP-, and NSE-positive glioma cells sorted from a human GBM biopsy, following removal of CD133-positive cells. All the CD133(-) subpopulations produced tumors, with no significant differences in survival or tumor take rates. However, there was a trend toward lower take rates for CD133(-) glioma subpopulations expressing GFAP and NSE. These findings suggest that the ability to form tumors may be a general trait associated with different glioma cell phenotypes, rather than a property limited to an exclusive subpopulation of glioma stem cells. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460538     DOI: 10.1158/0008-5472.CAN-09-3904

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Synergistic effect of retinoic acid and cytokines on the regulation of glial fibrillary acidic protein expression.

Authors:  Federico Herrera; Qi Chen; David Schubert
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

2.  Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Jintang He; Yashu Liu; Jaeman Byun; Anuradha Vivekanandan; Subramaniam Pennathur; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-10-24       Impact factor: 3.984

3.  Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas.

Authors:  Steve Scully; Ralph Francescone; Michael Faibish; Brooke Bentley; Sherry L Taylor; Dennis Oh; Robert Schapiro; Luis Moral; Wei Yan; Rong Shao
Journal:  J Neurosci       Date:  2012-09-12       Impact factor: 6.167

4.  c-Jun N-terminal kinase controls a negative loop in the regulation of glial fibrillary acidic protein expression by retinoic acid.

Authors:  F Herrera; P Maher; D Schubert
Journal:  Neuroscience       Date:  2012-02-15       Impact factor: 3.590

Review 5.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

6.  Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations.

Authors:  Johann Mar Gudbergsson; Esben Christensen; Serhii Kostrikov; Torben Moos; Meg Duroux; Andreas Kjær; Kasper Bendix Johnsen; Thomas Lars Andresen
Journal:  Mol Neurobiol       Date:  2020-07-06       Impact factor: 5.590

7.  Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.

Authors:  Anwar Hossain; Joy Gumin; Feng Gao; Javier Figueroa; Naoki Shinojima; Tatsuya Takezaki; Waldemar Priebe; Diana Villarreal; Seok-Gu Kang; Celine Joyce; Erik Sulman; Qianghu Wang; Frank C Marini; Michael Andreeff; Howard Colman; Frederick F Lang
Journal:  Stem Cells       Date:  2015-05-27       Impact factor: 6.277

8.  A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Authors:  Koppany Visnyei; Hideyuki Onodera; Robert Damoiseaux; Kuniyasu Saigusa; Syuzanna Petrosyan; David De Vries; Denise Ferrari; Jonathan Saxe; Eduard H Panosyan; Michael Masterman-Smith; Jack Mottahedeh; Kenneth A Bradley; Jing Huang; Chiara Sabatti; Ichiro Nakano; Harley I Kornblum
Journal:  Mol Cancer Ther       Date:  2011-08-22       Impact factor: 6.261

Review 9.  CD133: holy of grail of neuro-oncology or promiscuous red-herring?

Authors:  L K Donovan; G J Pilkington
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

10.  Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Authors:  Tooba A Cheema; Hiroaki Wakimoto; Peter E Fecci; Jianfang Ning; Toshihiko Kuroda; Deva S Jeyaretna; Robert L Martuza; Samuel D Rabkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.